The short answer: not banned, but on a real, narrowing path
If you've searched this because you saw a headline or a patient community post that alarmed you, take a breath first: compounded semaglutide and tirzepatide are still legal to buy today. Nothing has been finalized. But the direction is real, it's been building since April, and the most recent milestone — the close of the public comment period — just happened days ago, which is very likely why you're seeing more "semaglutide news" searches right now than usual.
Want to lock in your current access while it's still available?
DirectMeds offers physician-supervised compounded semaglutide from $249/month and tirzepatide from $397/month — no membership fee.
Check eligibility at DirectMeds →The real timeline — what's actually happened
| Date | What happened |
|---|---|
| Sept 2025 | FDA sends warning letters to 55+ compounded GLP-1 marketers over marketing language implying FDA-approved equivalence — an industry-wide sweep about labeling, not this proposal |
| April 30, 2026 | FDA formally proposes excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list — the specific action this page is about |
| March & June 2026 | Additional, separate waves of warning letters continue (roughly 30 and 25 letters respectively) — ongoing enforcement activity alongside the bulks list proposal |
| June 26, 2026 | FDA extends the public comment deadline from June 30 to July 30, 2026, after industry groups requested more time |
| July 30, 2026 | Comment period closes |
| Now (Aug 2026) | FDA is reviewing submitted comments; no final decision announced yet |
What the proposal actually targets — and what it doesn't
This is the part most coverage glosses over, and it matters a lot for what you should actually expect. The FDA's proposal is specifically about the 503B bulks list — the list of bulk drug substances that large-scale outsourcing facilities are legally allowed to use to compound medications ahead of individual prescriptions, typically to supply pharmacies and telehealth platforms at scale.
It does not eliminate compounding as a category. Traditional 503A compounding pharmacies — the ones that prepare a specific medication for a specific patient based on an individual prescription, the same legal framework used for things like custom-dosed hormones or allergy-friendly formulations — would still be permitted to compound semaglutide or tirzepatide for a patient with a genuine, documented clinical reason. The FDA has been explicit that cost or convenience alone doesn't count as that clinical reason; it typically means something like a documented allergy to an inactive ingredient in the branded product, a need for a dose increment that isn't commercially available, or a physical inability to use the standard injector device.
Curious whether your current provider is prepared for this?
See our full investigation into DirectMeds — licensing, pharmacy partners, and how they've responded to the regulatory environment so far.
Read the DirectMeds investigation →The salt form issue — a real, separate technical wrinkle
Worth knowing regardless of how the bulks list decision goes: some compounders use chemically distinct versions of these drugs — semaglutide sodium, for instance, rather than the base semaglutide used in Ozempic and Wegovy. These salt forms have not been proven safe and effective in humans or approved by the FDA as equivalent, and effectiveness can genuinely differ because of the salt form difference. This isn't new regulatory action — it's an existing, ongoing concern clinicians have raised — but it's a good, concrete question to ask any compounding provider directly: which exact form of the active ingredient are they using, and can they show you a Certificate of Analysis confirming it.
If you're currently on a compounded GLP-1, what to actually do
- Don't panic-switch today. Nothing has changed yet. Abruptly stopping a GLP-1 medication has its own real downside — research on discontinuation shows most patients regain a significant share of lost weight within a year of stopping.
- Ask your provider directly whether you'd have a documented clinical basis for continued 503A compounding if the broader rule is finalized — an allergy, a dosing need, or a delivery-device limitation, specifically.
- Price out the FDA-approved alternatives now, before you need them — see the comparison below. Having the number in hand removes the pressure of deciding under a deadline.
- Check your insurance or employer coverage. Roughly 40% of large employers now cover at least one GLP-1 medication for weight management — a share that's grown substantially and is worth rechecking even if you were denied before.
- If you're on Medicare, the Medicare GLP-1 Bridge program (launched July 2026) caps your copay at $50/month for Wegovy, Zepbound, or Foundayo if you qualify — see our full eligibility breakdown.
The real backup-option pricing, if you need it
| Option | Monthly cost | Notes |
|---|---|---|
| Compounded semaglutide (telehealth, today) | $249-297/mo | Still legal; regulatory picture narrowing |
| Oral Wegovy (semaglutide tablet) | $149-299/mo | FDA-approved, self-pay pricing via Novo Nordisk |
| Zepbound via LillyDirect | $299/mo | FDA-approved, flat rate regardless of dose |
| Orforglipron (Lilly's new oral GLP-1) | $149/mo | FDA-approved 2026, newest oral option |
| Medicare GLP-1 Bridge (if eligible) | $50/mo | Wegovy, Zepbound, or Foundayo through Dec 2027 |
The price gap between compounded and brand-name has genuinely narrowed over 2026 — it's no longer the 3-5x difference it was a year or two ago. That doesn't mean compounded isn't still cheaper for most people today, but it does mean the backup options are more realistic than they used to be if the regulatory picture tightens further.
Want to compare all your real options side by side?
See our complete, current breakdown of every legitimate GLP-1 access path — compounded, brand-name, and Medicare.
See every pricing option →What to watch next
The FDA hasn't given a specific timeline for its final decision after reviewing comments — these processes have taken anywhere from a few months to over a year in comparable cases. Realistically, expect this to remain an open question through at least the rest of 2026. We're tracking it directly and will update this page when the FDA actually rules, rather than when the next news cycle simply repeats the same April proposal.
Ready to check your options today?
Compounded access is still available right now — a free eligibility check takes about 10 minutes.
Check eligibility at DirectMeds →Frequently asked questions
Still weighing your options?
Compounded semaglutide from $249/month, tirzepatide from $397/month — physician-supervised, no membership fee.
Check eligibility at DirectMeds →Sources & references
- U.S. Food & Drug Administration. "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List." Press announcement, April 30, 2026. fda.gov
- Stanford Medicine. "Compounded GLP-1s: Why doctors worry and the FDA is cracking down." July 2026.
- Wilson Sonsini. "FDA Sends Warning Letters to More Than 50 GLP-1 Compounders and Manufacturers." October 2025.
- Novo Nordisk. Wegovy pill FDA approval and pricing announcement. December 22, 2025.
Medical disclaimer: This page is informational only and does not constitute medical or legal advice. Regulatory status can change; verify current information directly with FDA.gov before making treatment decisions. Consult a licensed physician before starting, stopping, or switching any medication.